Your browser doesn't support javascript.
loading
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga, José; Im, Seock-Ah; Iwata, Hiroji; Cortés, Javier; De Laurentiis, Michele; Jiang, Zefei; Arteaga, Carlos L; Jonat, Walter; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiello-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Takahashi, Masato; Vuylsteke, Peter; Hachemi, Soulef; Dharan, Bharani; Di Tomaso, Emmanuelle; Urban, Patrick; Massacesi, Cristian; Campone, Mario.
Afiliação
  • Baselga J; Department of Medicine and Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: baselgaj@mskcc.org.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Cortés J; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Instituto Oncológico Baselga, Hospital Quirónsalud, Barcelona, Spain.
  • De Laurentiis M; Department of Breast Oncology, Istituto Nazionale Tumouri Fondazione G Pascale, Naples, Italy.
  • Jiang Z; Department of Breast Cancer, Beijing 307 Hospital of PLA, Beijing, China.
  • Arteaga CL; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Jonat W; Department of Gynecology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Clemons M; Division of Medical Oncology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Ito Y; Department of Radiation Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Awada A; Medicine Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Chia S; Department of Medicine, BC Cancer Agency, Vancouver, BC, Canada.
  • Jagiello-Gruszfeld A; Department of Breast Cancer and Reconstruction Surgery, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
  • Pistilli B; Department of Oncology, Ospedale di Macerata, Macerata, Italy.
  • Tseng LM; Department of Surgery, Taipei Veterans General Hospital, National Yang Ming University, Taipei, Taiwan.
  • Hurvitz S; Division of Haematology-Oncology, Department of Medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Masuda N; Breast Oncology, Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Takahashi M; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Vuylsteke P; Department of Medical Oncology, Université Catholique de Louvain, CHU UCL, Namur, Belgium.
  • Hachemi S; Novartis Pharma SAS, Paris, France.
  • Dharan B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Di Tomaso E; Syros Pharmaceuticals, Watertown, MA, USA.
  • Urban P; Novartis Pharma AG, Basel, Switzerland.
  • Massacesi C; Novartis Pharma SAS, Paris, France.
  • Campone M; Institut de Cancérologie de l'Ouest-René Gauducheau Centre de Recherche en Cancérologie, Nantes, France.
Lancet Oncol ; 18(7): 904-916, 2017 07.
Article em En | MEDLINE | ID: mdl-28576675
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / DNA de Neoplasias / Protocolos de Quimioterapia Combinada Antineoplásica / Fosfatidilinositol 3-Quinases Tipo de estudo: Clinical_trials / Etiology_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / DNA de Neoplasias / Protocolos de Quimioterapia Combinada Antineoplásica / Fosfatidilinositol 3-Quinases Tipo de estudo: Clinical_trials / Etiology_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article